Dr. Achim Plum, Managing Director, has more than 18 years of management experience in the diagnostics industry with a focus on innovative molecular diagnostics, biomarker development, and personalized medicine. As CBO of the Curetis Group he represents ARES on the Curetis Executive Board. Achim joined the Curetis Group in 2015 from a Senior Management position at Siemens Healthcare where he was responsible for Diagnostic and BioScience Technology & Innovation. Prior to Siemens, Achim worked for eight years for the cancer MDx company Epigenomics, lastly as SVP Business & Strategy, that developed commercializes the first FDA-cleared liquid biopsy colorectal cancer screening test. Achim studied Genetics, Cell Biology and Biochemistry in Bonn, Germany, and Norwich UK. He obtained his Ph.D. in Molecular Genetics from the University of Bonn in 1999 and won numerous prizes and scholarships during his academic career.